Key result
DOACs account for ~85% of adverse drug reaction reports versus VKAs, mainly involving gastrointestinal disorders.
Why the study?
DOACs are associated with more gastrointestinal bleeding and fewer intracranial haemorrhages than VKAs, making it important to deepen knowledge of their safety profiles.
What are the differences in adverse drug reaction profiles between DOACs and VKAs in a spontaneous reporting system?
Observational (n=521)
What are the differences in adverse drug reaction profiles between DOACs and VKAs in a spontaneous reporting system?
Absolute Event Rate: 85.2% vs 14.8%
In a regional spontaneous reporting database, DOACs were more frequently associated with gastrointestinal adverse drug reactions, whereas VKAs were more commonly associated with blood and lymphatic system disorders.
Supports class-specific ADR monitoring; leaves open true incidence differences due to spontaneous reporting biases.
OBJECTIVE: Direct oral anticoagulants (DOACs) were developed to avoid the limitations of vitamin K antagonists (VKAs). DOACs are associated with a greater incidence of gastrointestinal bleeding and a smaller number of intracranial haemorrhages than VKAs. Therefore, it is important to deepen our knowledge of their safety profiles. The aim of this study was thus to analyse adverse drug reaction (ADR) reports on DOACs and VKAs using the Sicilian Spontaneous Reporting System (SRS) database. METHODS: All ADR reports with DOACs and VKAs as suspected drugs that were entered into the Sicilian SRS database during the period 2001-2019 were selected. In detail, all reports with the following single active substances were included: dabigatran etexilate, rivaroxaban, apixaban and edoxaban; acenocoumarol and warfarin were included as a comparator group. Descriptive statistical methodology was used to evaluate characteristics of the reported cases with a case-by-case assessment. RESULTS AND DISCUSSION: Out of 521 reports related to anticoagulants, 444 (85.2%) and 77 (14.8%) involved DOACs and VKAs, respectively. DOAC-related reports were mainly of gastrointestinal disorders. In contrast, VKAs were mostly associated with blood and lymphatic system disorders, injury, investigations and vascular disorders. Many more cases of ADRs in the form of gastrointestinal disorders concerned dabigatran etexilate (n = 179, 73.7%) than the other DOACs, while ADRs in the form of blood disorders were mainly associated with acenocoumarol (n = 27, 57.4%). The most commonly reported Preferred Terms for DOACs were dyspepsia (n = 89, 17.1%), upper abdominal pain (n = 41, 9.2%) and pruritus (n = 26, 5.8%), whereas for VKAs, they were anaemia (n = 21, 27.3%) and hypocoagulable state (n = 18, 3.5%). Potentially interacting concomitant medications particularly included antithrombotic agents (n = 19, 4.3%) for DOACs and proton-pump inhibitors (PPIs) (n = 37, 48.1%) and antithrombotic agents (n = 13, 16.9%) for VKAs. CONCLUSION: The ADRs most commonly associated with DOACs, especially dabigatran, were gastrointestinal disorders, particularly gastrointestinal bleeding. Our study also highlights the potential role of drug-drug interactions in the ADRs. The cases of gastrointestinal bleeding highlight the need for careful prescribing of DOACs and use of potentially interacting concomitant drugs.
No takes yet. Share an insight, caveat, or question.
Barbieri et al. (2021) conducted an observational in Adverse drug reactions (n=521). Direct oral anticoagulants (DOACs) vs. Vitamin K antagonists (VKAs) was evaluated on Adverse drug reaction reports. Among 521 adverse drug reaction reports, DOACs accounted for 85.2% of cases (mainly gastrointestinal disorders), while VKAs accounted for 14.8% (mainly blood and lymphatic disorders).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: